Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Sponsors › Genomics: Clinical Implementation › Healthcare Stakeholders Ask CMS Not to Limit Access to NGS Hereditary Cancer Risk Tests

Healthcare Stakeholders Ask CMS Not to Limit Access to NGS Hereditary Cancer Risk Tests

Feb 01, 2019
|
staff reporter

NEW YORK (GenomeWeb) – A group of 60 diverse healthcare companies and organizations has written to the Centers for Medicare & Medicaid Services, requesting the agency change its decision to restrict coverage of next-generation sequencing-based testing for hereditary cancer risk.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Cancer

  1. Oncologists See Clinical Trial Disruptions as Coronavirus Pandemic Continues

  2. Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

  3. OSE Immunotherapeutics Meets Primary Endpoint in Phase III Trial for HLA-A2 Positive Lung Cancer

  4. Metastatic Prostate Cancer Features Linked to Immunotherapy Response, Despite Low TMB

  5. Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.